Nick started working for Micronoma in February 2023. He was born and raised in San Diego, and went to college at UC Davis. As a Customer Care Manager, Nick’s main goal is to create a white glove customer experience at Micronoma. He is responsible for building our...
Up to two million incidentally detected pulmonary nodules (IPN) appear each year onimages coming from diagnostic scans that patients undergo for reasons unrelated tolung cancer. These nodules are abnormal growths (neoplasms) that form in the lungand, upon...
Analysts credit the Oncobiota microbiome-driven liquid biopsy platform for identifyingthe “infinite potential” of using microbiome markers to diagnose cancer.March 29, 2023. SAN DIEGO, Calif.–Based on an independent team of expert’srigorous evaluation of a broad...
Micronoma’s microbiome platform is breaking into its next phase with validation from the U.S. Food and Drug Administration. Last month, the San Diego-based company announced that the FDA has given its OncobiotaLUNG assay Breakthrough Device Designation. The...
The FDA has granted breakthrough device designation to the novel, microbiome-driven, liquid biopsy assay OncobiotaLUNG for the detection of lung carcinomas, according to a press release from developer Micronoma.1 The assay is one of the first blood microbiome–driven...
